yield (Scheme 1).8 This extension further generalizes our
strategy for the preparation of C-cyclopropylalkylamides and
allows direct access to these interesting functional groups
independent of the availability of imines 2 or alkynes 1.
Table 1. Conversions of C,C-dicyclopropylmethylamines 3
into Azepines 9 According to Scheme 2
Scheme 1. Preparation of C-Cyclopropylalkylamides from
Propargyl Phosphinamides
Recently, it has been demonstrated that molecular flex-
ibility in biological screening samples is often associated with
increased metabolism and decreased bioavailability.9 In
addition to minimizing this risk by cyclizing cyclopropyla-
lkylamides 3, 6, and 7, we were interested in expanding the
structural diversity of these novel building blocks by
selectively converting them into common 5-, 6-, and 7-
membered heterocyclic scaffolds used for biological screens.10
Indeed, we were able to take advantage of the functional
groups in 3, 6, and 7 for the straightforward preparation of
spirocyclic azepines, piperidines, and pyrrolidines. Although
N-heterocycles are often present in natural products and
pharmaceutically useful compounds, these azaspirocyclic
scaffolds represent novel structures for biological evaluation.
Ring-closing metathesis precursors 8a-g11,12 were readily
available in 65 to 96% yield via N-alkylation (NaH, HMPA,
allyl iodide) of phosphinamides 3a-g. While the ring-closing
event using 10 mol % of Grubbs’ second generation catalyst13
was rapid in dichloroethane,12a alkene isomerization to the
enamide was competitive (azepine/enamide ∼1:1).12b,14 How-
ever, this undesired isomerization pathway could be mini-
mized by lowering the reaction temperature (CH2Cl2, reflux)
leading to the desired 1H-azepines 9a-g in 63-84% yield
(Scheme 2). Functionalization was tolerated on both the arene
segment as well as the alkyne side chain, and no ring opening
of cyclopropanes was observed (Table 1).15
a Yield of isolated products.
We also envisioned the preparation of smaller nitrogen-
containing heterocycles using a reductive amination strategy.
The ω-disubstituted alkene moiety in 3 and 6 was easily
converted to an aryl ketone under Johnson-Lemieux16
conditions (Scheme 3). We were unable to affect reductive
amination under Lewis acidic conditions (BF3‚OEt2/Ph3SiH17
or TiCl4/Et3SiH), but a simple three-step, one-pot protocol
involving N-deprotection (HCl/MeOH) followed by reductive
amination (NaBH3CN, MeOH) and acylation (AcCl, DIPEA)
(8) Zn(CH2I)2‚DME was used for mmole-scale preparations of C,C-
dicyclopropylmethylamides 3, 6, and 7 as a safer alternative to Zn(CH2I)2
without noticeable attenuation of reactivity. Cf. Charette, A. B.; Prescott,
S.; Brochu, C. J. Org. Chem. 1995, 60, 1081.
Scheme 2. Azepine Formation by Sequential N-Allylation/
Ring-Closing Metathesis
(9) Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K.
W.; Kopple, K. D. J. Med. Chem. 2002, 45, 2615.
(10) Lee, M.-L.; Schneider, G. J. Comb. Chem. 2001, 3, 284.
(11) (a) Schuster, M.; Blechert, S. Angew. Chem., Int. Ed. Engl. 1997,
36, 2037. (b) Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413. (c)
Fu¨rstner, A. Angew. Chem., Int. Ed. 2000, 39, 3012.
(12) For the preparation of azepines by ring-closing metathesis, cf. (a)
Hoffmann, T.; Waibel, R.; Gmeiner, P. J. Org. Chem. 2003, 68, 62. (b)
Wipf, P.; Rector, S. R.; Takahashi, H. J. Am. Chem. Soc. 2002, 124, 14848.
(c) Furstner, A.; Guth, O.; Duffels, A.; Seidel, G.; Liebl, M.; Gabor, B.;
Mynott, R. Chem. Eur. J. 2001, 7, 4811. (d) Fu, G. C.; Grubbs, R. H. J.
Am. Chem. Soc. 1992, 114, 7324.
(13) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1,
953.
(14) (a) Sutton, A. E.; Seigal, B. A.; Finnegan, D. F.; Snapper, M. L. J.
Am. Chem. Soc. 2002, 124, 13390. (b) Lehman, S. E., Jr.; Schwendeman,
J. E.; O′Donnell, P. M.; Wagener, K. B. Inorg. Chim. Acta 2003, 345, 190.
(c) Hong, S. H.; Day, M. W.; Grubbs, R. H. J. Am. Chem. Soc. 2004, 126,
7414.
3010
Org. Lett., Vol. 6, No. 17, 2004